HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results. This is an ASCO Meeting ...

“I Have a Lot of Pills in My Bag, You Know”: Institutional Norms in the Provision of Hope in Phase I Clinical Cancer Trials ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

In sharp contrast to many other cancer types, the incidence and mortality of endometrial cancer continue to grow. This unfortunate trend is, in no small part, a result of the worldwide obesity ...

Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia ...

The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.

Thirty-nine patients with advanced metastatic melanoma, colorectal cancer (CRC), castrate-resistant prostate cancer, non–small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC) received a single ...

The article by Avet-Loiseau et al entitled “International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” (Journal of ...

Women with MBC were randomly assigned to first-line therapy with paclitaxel 175 mg/m 2 every 3 weeks plus lapatinib 1,500 mg/d or placebo. A preplanned retrospective evaluation of HER-2 status was ...

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. This is an ASCO Meeting Abstract from ...

Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days ABSTRACT: Melatonin, the chief secretory product of the pineal gland, is a ...

Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018. Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have ...